Vice President, Clinical Development, Pediatric and Maternal Vaccines
Moderna Biotech UK, Inc, United Kingdom
Disclosure(s): Moderna, Inc.: Employee, Stocks/Bonds (Public Company)
In 2022 I joined Moderna UK in a global role as Vice President, Clinical Development of Maternal and Paediatric Vaccines, where I am primarily working on the development of vaccines against Respiratory Syncytial Virus (RSV).
Prior to this I was Professor of Paediatrics and Vaccinology at the Oxford Vaccine Group, University of Oxford, where I had worked since 2003, combining oversight of clinical trials of vaccines against Ebola Virus, meningococcus, pneumococcus, RSV, Influenza and SARS-CoV-2 with clinical work as a general paediatrician. From 2017 until 2022 I was the director of the NIHR funded National Immunisation Schedule Evaluation Consortium (NISEC), which led the studies of mixed COVID-19 vaccine schedules (Com-Cov, COV-Boost, Com-Flu-Cov)